STOCK TITAN
  1. Home
  2. News
  3. IRTC

iRhythm Technologies Inc - IRTC STOCK NEWS

Welcome to our dedicated news page for iRhythm Technologies (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iRhythm Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iRhythm Technologies's position in the market.

News
iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024
Rhea-AI Summary
iRhythm Technologies, Inc. (NASDAQ:IRTC) will report its first quarter 2024 financial results on May 2, 2024. The company focuses on digital healthcare solutions to detect, prevent, and predict diseases. The management team will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties can access the webcast on the investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Senior Notes Due 2029, Including Full Exercise of Initial Purchasers’ $86.25 Million Option to Purchase Additional Notes
Rhea-AI Summary
iRhythm Technologies, Inc. announced the closing of its offering of 1.50% Convertible Senior Notes due 2029, raising $661.25 million in gross proceeds. The notes are convertible at the option of holders and will bear interest at 1.50% per year, with an initial conversion rate of 6.7927 shares of iRhythm's common stock per $1,000 principal amount of notes. The net proceeds from the offering are estimated to be approximately $643.6 million, with intended uses for general corporate purposes and repayment of debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
none
-
News
iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029
Rhea-AI Summary
iRhythm Technologies, Inc. announced the pricing of $575.0 million Convertible Senior Notes due 2029 in a private placement. The offering size was increased from $450.0 million, with an option for additional notes. The notes will bear interest at 1.50% per year and mature on September 1, 2029. Holders can convert the notes under certain conditions. iRhythm expects to use the net proceeds for various purposes, including repaying loans and entering capped call transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
News
iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes
Rhea-AI Summary
iRhythm Technologies, Inc. announced a private placement of $450.0 million aggregate principal amount of Convertible Senior Notes due 2029, with additional notes option. The notes will be senior, unsecured obligations, convertible under certain conditions. The company plans to use proceeds for various purposes including repayment of debt, capped call transactions, and share repurchases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
none
-
News
iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients
Rhea-AI Summary
iRhythm Technologies, Inc. (NASDAQ:IRTC) partners with Epic to integrate Zio long-term continuous monitoring services into the healthcare provider's EHR platforms, aiming to improve operational efficiency and patient care. The collaboration is estimated to save organizations up to 75% of integration time, with iRhythm already having over 1.5 million registrations through EHR-integrated customers, resulting in significant cost and time savings. This strategic move positions iRhythm as the first medical device company to join the Epic community, enhancing access to Zio services for healthcare providers and patients nationwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
News
iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
iRhythm Technologies, Inc. (IRTC) reported strong financial results for Q4 2023 and full year 2023, with revenue growth of 17.7% and 19.9% respectively. Despite a net loss increase, the company showed improvements in adjusted EBITDA. Operational highlights include significant progress in Zio monitor transition and upcoming data presentations. The CEO highlighted revenue growth, international expansion efforts, and operational improvements in 2023, with a positive outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.69%
Tags
earnings
News
iRhythm Technologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
iRhythm Technologies, Inc. (NASDAQ:IRTC) will release financial results for Q4 and full year 2023 on February 22, 2024. A conference call will follow, accessible via webcast on the investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences earnings
-
News
iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
iRhythm Technologies, Inc. (IRTC) announced preliminary fourth quarter operational highlights and a business update at the 42nd Annual J.P. Morgan Healthcare Conference. The company reported a 22% growth in fourth quarter 2023 patient registrations compared to 2022, as well as significant achievements in clinical diagnostic yield, FDA submissions, CE mark approvals, and financial outlook. The company expects revenue for 2024 to be approximately $575 million to $585 million, representing growth of approximately 18-20% compared to 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
earnings
-
News
Largest Ever Real-World Evidence Study of Ambulatory Cardiac Monitoring Demonstrates Clinical Superiority of iRhythm's Zio Long-Term Continuous Monitoring Service
Rhea-AI Summary
iRhythm Technologies, Inc. (IRTC) announces that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study have been published in the American Heart Journal, demonstrating higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ambulatory cardiac monitoring (ACM) products. The study found that Zio LTCM was independently associated with the highest yield of clinical arrhythmia encounter diagnosis and lowest likelihood of retest, as well as minimized subsequent health care spending, compared to traditional Holter monitors or non-continuous event monitors. The study also revealed that LTCM was associated with the lowest increase in health care resource utilization and costs, including fewer emergency department visits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.99%
Tags
none
News
iRhythm Technologies Receives European Union’s CE Marking Under Medical Device Regulation (EU MDR) for its Zio® monitor and ZEUS System
Rhea-AI Summary
iRhythm Technologies, Inc. (NASDAQ:IRTC) announced that its Zio monitor ECG System has received CE mark certification under the EU MDR, reinforcing its position as a leading innovation in ambulatory cardiac monitoring. The Zio monitor is thinner, lighter, and smaller compared to its predecessor, Zio XT, and incorporates the ZEUS (Zio ECG Utilization Software) System, iRhythm’s advanced deep-learned AI algorithm. The company plans to expand its market presence in Europe to address the significant unmet clinical need for improved arrhythmia detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Stock IRTC logo
iRhythm Technologies Inc

Nasdaq:IRTC

IRTC Rankings

#1402 Ranked by Market Cap
#4270 Ranked by Stock Gains
N/A Ranked by Dividends

IRTC Stock Data

3.52B
30.66M
1.05%
109.1%
8.24%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Francisco

About IRTC

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.